Effective screening for major aneuploidies can be provided in the first trimester of
pregnancy. Screening by a combination of fetal nuchal translucency and maternal serum …

There is extensive evidence that effective screening for major chromosomal abnormalities
can be provided in the first trimester of pregnancy. Prospective studies in a total of 200,868 …

Purpose: Prenatal screening for Down syndrome has improved, but the number of resulting
invasive diagnostic procedures remains problematic. Measurement of circulating cell-free …

OBJECTIVE: We sought to evaluate a multiplexed massively parallel shotgun sequencing
assay for noninvasive trisomy 21 detection using circulating cell-free fetal DNA. STUDY …

Background It is uncertain how best to screen pregnant women for the presence of fetal
Down's syndrome: to perform first-trimester screening, to perform second-trimester …

Background Circulating markers indicating the instability of atherosclerotic plaques could
have diagnostic value in unstable angina or acute myocardial infarction. We evaluated …

Background Screening for aneuploid pregnancies is routinely performed after 15 weeks of
gestation and has a sensitivity of approximately 65 percent, with a false positive rate of 5 …

Abstract Objectives The National Institute of Child Health and Human Development Fetal
Cell Isolation Study (NIFTY) is a prospective, multicenter clinical project to develop non …

Human matrix metalloproteinases (MMPs) belong to the M10 family of the MA clan of
endopeptidases. They are ubiquitarian enzymes, structurally characterized by an active site …

The trials performed worldwide toward noninvasive prenatal diagnosis (NIPD) of Down's
syndrome (or trisomy 21) have shown the commercial and medical potential of NIPD …